News

Read more about the latest developments at Curate Biosciences

News

Addressing biopharma’s manufacturing talent gap may require building a new image

September 20, 2022

A rebranding of biopharmaceutical manufacturing as a career, and a rethink of the educational programs that feed the field, could help address a growing talent crunch.

VIEW ARTICLE

Curate Biosciences Appoints Daniel Getts, Ph.D. to its Board of Directors

August 15, 2022

Curate Biosciences, a key enabling technology company for cell therapy manufacturing, today announced that Daniel Getts, Ph.D., cofounder and CEO of Myeloid Therapeutics, has been appointed to its Board of Directors. Dr. Getts is an immunologist by training and a serial entrepreneur with a proven track record in building and financing companies focused on creating next-generation immunotherapies.

VIEW ARTICLE

Separating More T Cells for Immunotherapy

April 20, 2022

To capture more T cells for such autologous cell therapy, City of Hope—one of the largest cancer research and treatment organizations in the U.S.—plans to integrate the Curate CELL PROCESSING SYSTEM into its workflow to manufacture investigational CAR-T cell immunotherapy. This system takes a new approach to T-cell separation.

VIEW ARTICLE

US cancer research institute validated Curate's cell process system

April 5, 2022

City of Hope, one of the largest cancer research and treatment organizations in the US, has given a thumbs up to the Curate Biosciences' cell processing system for advanced cell separation. Having evaluated the platform, the Beckman Research Institute of City of Hope now plans to integrate the technology into its workflow to manufacture investigational CAR-T cell immunotherapy.

VIEW ARTICLE

Curate Biosciences and City of Hope Evaluate Innovative Cell Separation for HIV CAR-T Cell Therapy Production

April 5, 2022

Curate Biosciences, a key enabling technology company for cell therapy manufacturing, announced the first outcome of its Technology Access Program, which is dedicated to converting research into real-world treatments and cures as rapidly as possible. City of Hope, one of the largest cancer research and treatment organizations in the United States, has evaluated the Curate® Cell Processing System for advanced cell separation and plans to integrate the platform into its workflow to manufacture investigational CAR-T cell immunotherapy.

VIEW ARTICLE

GPB Scientific becomes Curate Biosciences, targets 50% reduction in autologous cell therapy costs

February 10, 2022

GPB Scientific is now known as Curate Biosciences, a name it says reflects more the work it is doing for cell and gene therapy providers.
The company has spent six years working on a platform focused on cell potency and recovery; it says it has cracked one of the biggest problems in cell therapy; extracting enough potent cells to treat chronically sick patients.

VIEW ARTICLE

GPB Scientific announces go-to-market kickoff under new brand: Curate Biosciences

February 8, 2022

GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate® Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company’s advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the system’s upcoming commercial introduction. Anticipating the commercial launch, the company is changing its name to “Curate Biosciences” to better communicate its benefits to the gene and cell therapy industry.

VIEW ARTICLE

GPB Scientific Accelerates Cell Therapy Manufacturing with Key Hires

January 7, 2022

GPB Scientific, Inc., a key enabling technology company for cell therapy manufacturing, announced the hiring of Gaurav Vij and Joan Haab, PhD, as it prepares to make cell therapy available to the largest number of patients. Mr. Vij will serve as the company’s first Chief Business Officer, and Dr. Haab as its first Senior Vice President, Manufacturing and Supply Chain Operations, key positions for driving GPB’s growth as it moves to expand patient access to life-saving cell therapies…

VIEW ARTICLE

GPB Scientific Increases Second Tranche of Venture-backed Growth Financing from $10 to $ 18 million to Support Commercialization of Curate® Cell Processing System

May 27, 2021

GPB Scientific, Inc., a developer of transformative cell processing technology for next generation cell and gene therapies, today announced raising an additional $18 million in capital as part of a previously announced financing, including commitments from existing investors Vensana Capital and Amgen Ventures, and from a new undisclosed healthcare investor. This financing will support expanded placements of GPB’s Curate® Cell Processing System into partner facilities to enable optimized development and manufacturing in CAR-T and TCR programs, as well as development of the platform’s utility in additional types of cell and gene therapy applications…

VIEW ARTICLE

GPB Scientific Announces $25.5 Million Financing from Vensana Capital and Amgen Ventures

April 2, 2020

GPB Scientific, Inc., a developer of breakthrough technologies for therapeutic cell production and bioprocessing, today announced a $25.5 million funding commitment. The financing is led by Vensana Capital alongside strategic investor Amgen Ventures with ongoing participation by existing investors…

VIEW ARTICLE

GPB Scientific Awarded Phase II of $2.2M NIH Grant to Complete Development of Microfluidic CAR-T Cell Processing Device

June 3, 2019

GPB Scientific LLC announced that the NIH completed its review or its achievement of Phase I milestones and authorized Phase II funding under a $2.2M NIH STTR Award. The award by the National Cancer Institute of the National Institutes of Health supports work by GPB Scientific, in collaboration with the University of Maryland School of Medicine and Princeton University, to scale up GPB Scientific’s microfluidic cell separation technology. GPB Scientific’s innovation displaces current centrifuge-based systems for selecting cells, such as isolating a patient’s own white blood cells from red cells and platelets to manufacture ground-breaking CAR-T cancer therapies…

VIEW ARTICLE